More than 99% of Italy’s coronavirus fatalities were people who suffered from previous medical conditions, according to a study by the country’s national health authority.
After deaths from the virus reached more than 2,500, with a 150% increase in the past week, health authorities have been combing through data to provide clues to help combat the spread of the disease.
Prime Minister Giuseppe Conte’s government is evaluating whether to extend a nationwide lockdown beyond the beginning of April, daily La Stampa reported Wednesday. Italy has more than 31,500 confirmed cases of the illness.
Italy Coronavirus Deaths
By prior illnesses (%)
The new study could provide insight into why Italy’s death rate, at about 8% of total infected people, is higher than in other countries.
The Rome-based institute has examined medical records of about 18% of the country’s coronavirus fatalities, finding that just three victims, or 0.8% of the total, had no previous pathology. Almost half of the victims suffered from at least three prior illnesses and about a fourth had either one or two previous conditions.More than 75% had high blood pressure, about 35% had diabetes and a third suffered from heart disease.
Threat to the Elderly
The median age of the infected is 63 but most of those who die are older
The average age of those who’ve died from the virus in Italy is 79.5. As of March 17, 17 people under 50 had died from the disease. All of Italy’s victims under 40 have been males with serious existing medical conditions.
While data released Tuesday point to a slowdown in the increase of cases, with a 12.6% rise, a separate study shows Italy could be underestimating the real number of cases by testing only patients presenting symptoms.
According to the GIMBE Foundation, about 100,000 Italians have contracted the virus, daily Il Sole 24 Ore reported. That would bring back the country’s death rate closer to the global average of about 2%.
HOW D’OXYVA CAN HELP?
Circularity is already in Phase 3 human clinical trials with most of the top ten U.S. university research institutions with D’OXYVA for FDA approval for rapidly treating chronic conditions such as diabetic wounds and hypertension, and fighting against COVID-19 with an already FDA-approved simple, non-toxic, and widely used molecule in nearly all hospitals around the world.
D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.
The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.